Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing phase 4 study of satralizumab in Chinese AQP4-IgG positive NMOSD
CTR20220584Phase 4Active
- Sponsor
- Roche
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Roche. Primary endpoints: Annualized relapse rate from baseline to Week 48 and Safety and tolerability. Started Aug 2022; status: active.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20220584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220584.